在2024年ASCO年会上公布的研究结果显示,在疗效方面,所有患者的客观应答率(ORR)为16%,中位应答持续时间为5.5个月(95%CI,4.1个月,无法评估)。12周和24周临床获益率(CBR)分别为50%和29%。 其他疗效数据显示,接受1.6mg/kg治疗的患者的ORR和CBR分别为6%和75%。这些患者的中位PFS为5.1个月(95%CI,2.8-6.8)。
First-in-human study of ABBV-400, a novel c-Met–targeting antibody-drug conjugate, in advanced solid tumors: Results in colorectal cancer. 2024 ASCO Abstract 3515. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met P...
2024年ASCO年会上公布的结果显示,所有患者的客观缓解率为16%,中位缓解持续时间为5.5个月。12周和24周的临床获益率分别为50%和29%。不同剂量的额外疗效数据显示,1.6 mg/kg、2.4 mg/kg和3.0 mg/kg剂量组的客观缓解率分别为6%、18%和24%,临床获益率分别为75%、78%和68%,中位PFS分别为5.1个月、5.3个月和...
400 was initiated for adults with advanced solid tumors and progression on standard therapies (NCT05029882); results from dose escalation (ESC) at doses 1.6–6.0 mg/kg once every 3 weeks (Q3W) were previously presented and showed preliminary efficacy (Sharma et al. ASCO 2023. Abstract 3015)....
1. Sharma M, et al. ASCO 2023. Abstract 3015.Clinical trial information: NCT05029882. 展开 关键词: 6 5 5 4 3 3 3 DOI: 10.1200/JCO.2024.42.16_suppl.3030 年份: 2024 收藏 引用 批量引用 报错 分享 全部来源 求助全文 Wolters Kluwer 相似文献...
Conference|Gastrointestinal Cancers Symposium (ASCO GI) Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC. This is a modal window. The Playback API requ...
在2024年ASCO年会上公布的研究结果显示,在疗效方面,所有患者的客观应答率(ORR)为16%,中位应答持续时间为5.5个月(95%CI,4.1个月,无法评估)。12周和24周临床获益率(CBR)分别为50%和29%。 其他疗效数据显示,接受1.6mg/kg治疗的患者的ORR和CBR分别为6%和75%。这些患者的中位PFS为5.1个月(95%CI,2.8-6.8)。
ASCO 2023. Abstract 3015.Clinical trial information: NCT05029882.Carla Biesdorf de AlmeidaAbbVie Inc., North Chicago, ILBenjamin EngelhardtAbbVie Inc., Ludwigshafen, GermanyHeiko BabelAbbVie Deutschland GmbH & Co. KG, Ludwigshafen Am Rhein, GermanyJesus D Badillo...
Conference|Gastrointestinal Cancers Symposium (ASCO GI) Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC. Play Vide...
Conference|Gastrointestinal Cancers Symposium (ASCO GI) Kanwal P.S. Raghav, MD, MBBS, discusses a phase 2 study of ABBV-400 plus 5-FU, folinic acid, and bevacizumab in pretreated patients with metastatic CRC. Video Play...